COVID-19 and cardiovascular diseases

COVID-19 and cardiovascular diseases

First cases of new coronavirus infection were registered in December 2019. The COVID-19 outbreak was declared a global pandemic. COVID-19 is much more dangerous for people older than 65. It is well known that cardiovascular diseases are more affecting older patients as well. The potentially dangerou...

Full description

Bibliographic Details
Main Authors:	I. E. Chazova, O. I. Mironova
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2020-10-01
Series:	Терапевтический архив
Subjects:	covid-19 new coronavirus infection pandemic cardiovascular diseases arterial hypertension acute coronary syndrome myocarditis pulmonary embolism angiotensin-converting enzyme inhibitors angiotensin ii receptor blockers
Online Access:	https://ter-arkhiv.ru/0040-3660/article/viewFile/46843/31992

Similar Items

The problem of determining the efficiency of treatmentin the era of evidence-based medicine: international and domestic experience
by: S R Gilyarevsky
Published: (2014-06-01)

2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
by: Luigi Cappannoli, et al.
Published: (2020-12-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Angiotensin-converting enzyme inhibitors or sartans in patients at high risk for cardiovascular events: a wrong question or an undesirable answer
by: S R Gilyarevsky, et al.
Published: (2013-03-01)

Effectiveness of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers on total and cardiovascular mortality and morbidity in primary prevention: A nationwide study based on French Health Insurance Data (SNDS)
by: Emmanuel Oger, et al.
Published: (2022-04-01)

Impact of drug therapy on the risk of death in patients with coronary heart disease (according to the data of registry of cardiovascular diseases, RECVASA)
by: K. G Pereverzeva, et al.
Published: (2017-09-01)

Angiotensin-Converting Enzyme Inhibitor / Angiotensin II Receptor Blocker in COVID-19: a Double-edged Sword or a Myth
by: Kunal Bikram Shaha, et al.
Published: (2020-05-01)

Associations Between the Use of Renin–Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies
by: Xiao-Ce Dai, et al.
Published: (2021-04-01)

Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19
by: Naci Şenkal, et al.
Published: (2020-07-01)

Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells
by: Ilaria Caputo, et al.
Published: (2022-05-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

A study of prognosis and outcome of COVID-19-infected hypertensive patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
by: M S Bharath, et al.
Published: (2024-01-01)

Angiotensin‐Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID‐19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System
by: Jaejin An, et al.
Published: (2021-02-01)

Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
by: Rohan Khera, et al.
Published: (2021-07-01)

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study
by: Ju Hwan Kim, et al.
Published: (2020-12-01)

Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series
by: Mishita Goel, et al.
Published: (2020-08-01)

COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system
by: Jaejin An, et al.
Published: (2021-06-01)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
by: Si-Hyuck Kang, et al.
Published: (2021-06-01)

Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension
by: Jinwoo Lee, et al.
Published: (2021-03-01)

Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension
by: Sonali R. Gnanenthiran, et al.
Published: (2022-09-01)

Study Hypothesis: Age, Gender, Presence of Diabetes Mellitus or Hypertension, and Anti-Hypertensive Drugs Are Independent Risk Factors for COVID-19 Mortality
by: Faruk Karandere, et al.
Published: (2023-01-01)

Renin–angiotensin–aldosterone pathway modulators in chronic kidney disease: A comparative review
by: Saeed Alshahrani
Published: (2023-02-01)

Bradykinin-Mediated Angioedema Induced by Commonly Used Cardiovascular Drugs
by: Janina Hahn, et al.
Published: (2023-09-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

Impact of Renin‐Angiotensin System Inhibitors on Long‐Term Clinical Outcomes of Patients With Coronary Artery Spasm
by: Byoung Geol Choi, et al.
Published: (2016-07-01)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
by: Seok Hui Kang, et al.
Published: (2023-05-01)

A high sodium intake reduces antiproteinuric response to renin–angiotensin–aldosterone system blockade in kidney transplant recipients
by: Elena Monfá, et al.
Published: (2016-09-01)

Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis
by: Andrea Laurentius, et al.
Published: (2021-02-01)

Hypertension, medications, and risk of severe COVID‐19: A Massachusetts community‐based observational study
by: Ann Z. Bauer, et al.
Published: (2021-01-01)

Inhibitors of the renin-angiotensin system ameliorates clinical and pathological aspects of experimentally induced nephrotoxic serum nephritis
by: M. E. Ougaard, et al.
Published: (2018-10-01)

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
by: Juan Meng, et al.
Published: (2020-01-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

Management of diabetic hypertensives
by: Jai Ganesh, et al.
Published: (2011-01-01)

Long-term use of renin-angiotensin-system inhibitors after acute myocardial infarction is not associated with survival benefits: Analysis of data from the Korean acute myocardial infarction registry-national institutes of health registry
by: Chan Soon Park, et al.
Published: (2022-08-01)

The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
by: Tao Liu, et al.
Published: (2023-01-01)

Effect of an angiotensin-converting-enzyme inhibitor on the plasma concentration of cytokines and vasoactive molecules in patients with coronary heart disease and hypertension
by: A A Khadartsev, et al.
Published: (2017-12-01)

A systematic review and meta‐analysis of the use of renin‐angiotensin system drugs and COVID‐19 clinical outcomes: What is the evidence so far?
by: Amanj Kurdi, et al.
Published: (2020-12-01)

Sartans in cardiological practice: new possibilities in therapy of cardiovascular diseases
by: O G Smolenskaya
Published: (2009-06-01)

Renin-angiotensin system inhibitors improve the survival of cholangiocarcinoma: a propensity score-matched cohort study
by: Xiao-Xu Zhu, et al.
Published: (2023-09-01)

Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective
by: Hee-Sung Kim, et al.
Published: (2021-02-01)